Institute for Clinical and Economic Review Publishes Final Evidence Report and Policy Recommendations on Therapies for Lupus Nephritis
April 17, 2021
April 17, 2021
BOSTON, Massachusetts, April 17 (TNSRep) -- The Institute for Clinical and Economic Review issued the following announcement on April 16, 2021:
The Institute for Clinical and Economic Review (ICER) released a Final Evidence Report assessing the comparative clinical effectiveness and value of belimumab (Benlysta(R), GlaxoSmithKline) and voclosporin (Lupkynis(TM), Aurinia) for the treatment of lupus nephritis (LN). The FDA approved belimumab on December 17, 2020 and voclosporin on Jan . . .
The Institute for Clinical and Economic Review (ICER) released a Final Evidence Report assessing the comparative clinical effectiveness and value of belimumab (Benlysta(R), GlaxoSmithKline) and voclosporin (Lupkynis(TM), Aurinia) for the treatment of lupus nephritis (LN). The FDA approved belimumab on December 17, 2020 and voclosporin on Jan . . .